An observational study evaluating long-acting injectable cabotegravir (CAB-LA; APRETUDE) healthcare provider and user experience and utilization for pre-exposure prophylaxis (PrEP) against HIV in Canada (223857)

Study identification

• EU PAS number:
  EUPAS1000000801
• Study ID:
  1000000801
• Official title and acronym:
  An observational study evaluating long-acting injectable cabotegravir (CAB-LA; APRETUDE) healthcare provider and user experience and utilization for pre-exposure prophylaxis (PrEP) against HIV in Canada (223857)
• DARWIN EU® study:
  No
• Study countries:
  Canada
• Study description:
  No information provided.
• Study status:
  Planned

Research institutions and networks

Institutions

ViiV Healthcare

Broadstreet HEOR

Study timelines

Date when funding contract was signed

Planned:03/11/2025

Actual:01/11/2024

Study start date

Planned:19/12/2025

Date of final study report

Planned:01/02/2028

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

ViiV Healthcare ULC

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only